RS57875B1 - Kombinacija regorafeniba i acetilsalicilne kiseline za lečenje kolorektalnog kancera - Google Patents

Kombinacija regorafeniba i acetilsalicilne kiseline za lečenje kolorektalnog kancera

Info

Publication number
RS57875B1
RS57875B1 RS20181015A RSP20181015A RS57875B1 RS 57875 B1 RS57875 B1 RS 57875B1 RS 20181015 A RS20181015 A RS 20181015A RS P20181015 A RSP20181015 A RS P20181015A RS 57875 B1 RS57875 B1 RS 57875B1
Authority
RS
Serbia
Prior art keywords
acid
regorafenib
limited
colorectal cancer
acetylsalicylic acid
Prior art date
Application number
RS20181015A
Other languages
English (en)
Serbian (sr)
Inventor
Olaf Weber
Karl Ziegelbauer
Original Assignee
Bayer Pharma AG
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46963566&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS57875(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG, Bayer Ag filed Critical Bayer Pharma AG
Publication of RS57875B1 publication Critical patent/RS57875B1/sr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • A61K31/612Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RS20181015A 2012-09-25 2013-09-23 Kombinacija regorafeniba i acetilsalicilne kiseline za lečenje kolorektalnog kancera RS57875B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12185852 2012-09-25
PCT/EP2013/069735 WO2014048881A1 (en) 2012-09-25 2013-09-23 Combination of regorafenib and acetylsalicylic acid for treating cancer
EP13770659.4A EP2900269B1 (en) 2012-09-25 2013-09-23 Combination of regorafenib and acetylsalicylic acid for treating colorectal cancer

Publications (1)

Publication Number Publication Date
RS57875B1 true RS57875B1 (sr) 2018-12-31

Family

ID=46963566

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20181015A RS57875B1 (sr) 2012-09-25 2013-09-23 Kombinacija regorafeniba i acetilsalicilne kiseline za lečenje kolorektalnog kancera

Country Status (29)

Country Link
US (1) US10898500B2 (https=)
EP (1) EP2900269B1 (https=)
JP (1) JP6294888B2 (https=)
KR (1) KR102210575B1 (https=)
CN (1) CN104994876A (https=)
AU (1) AU2013322854B2 (https=)
BR (1) BR112015006686B1 (https=)
CA (1) CA2885688C (https=)
CL (1) CL2015000744A1 (https=)
CY (1) CY1120939T1 (https=)
DK (1) DK2900269T3 (https=)
EA (1) EA032023B1 (https=)
ES (1) ES2687985T3 (https=)
HK (1) HK1214169A1 (https=)
HR (1) HRP20181462T1 (https=)
HU (1) HUE039878T2 (https=)
IL (1) IL237690B (https=)
LT (1) LT2900269T (https=)
MX (1) MX357035B (https=)
MY (1) MY183969A (https=)
NZ (1) NZ705860A (https=)
PH (1) PH12015500587A1 (https=)
PL (1) PL2900269T3 (https=)
PT (1) PT2900269T (https=)
RS (1) RS57875B1 (https=)
SG (2) SG11201501963RA (https=)
SI (1) SI2900269T1 (https=)
WO (1) WO2014048881A1 (https=)
ZA (1) ZA201502840B (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2014DN09346A (https=) 2012-06-13 2015-07-17 Hoffmann La Roche
KR102179599B1 (ko) 2012-09-25 2020-11-19 에프. 호프만-라 로슈 아게 이환형 유도체
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
CN105764905B (zh) 2013-11-26 2019-06-07 豪夫迈·罗氏有限公司 新的八氢-环丁二烯并[1,2-c;3,4-c’]二吡咯-2基
WO2015144609A1 (en) 2014-03-26 2015-10-01 F. Hoffmann-La Roche Ag Condensed [1,4]diazepine compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors
CN106103446B (zh) 2014-03-26 2019-07-30 豪夫迈·罗氏有限公司 作为自分泌运动因子(atx)和溶血磷脂酸(lpa)生产抑制剂的二环化合物
CN104829523B (zh) * 2014-04-30 2017-10-31 药源药物化学(上海)有限公司 瑞戈非尼盐及其晶型、制备方法
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
CA2992889A1 (en) 2015-09-04 2017-03-09 F. Hoffmann-La Roche Ag Phenoxymethyl derivatives
CN105267167A (zh) * 2015-09-11 2016-01-27 江苏嘉逸医药有限公司 一种瑞戈非尼口服固体药物组合物的制备方法
CR20180057A (es) 2015-09-24 2018-04-02 Hoffmann La Roche Nuevos compuestos biciclicos como inhibidores duales de atx/ca.
RU2018112230A (ru) 2015-09-24 2019-10-30 Ф. Хоффманн-Ля Рош Аг Бициклические соединения в качестве ингибиторов atx
KR20180054830A (ko) 2015-09-24 2018-05-24 에프. 호프만-라 로슈 아게 오토탁신(atx) 억제제로서의 이환형 화합물
AU2016328365B2 (en) 2015-09-24 2020-04-23 F. Hoffmann-La Roche Ag New bicyclic compounds as dual ATX/CA inhibitors
WO2018002124A1 (en) * 2016-06-28 2018-01-04 Asamedic As Two-component composition
SG11201908560SA (en) 2017-03-16 2019-10-30 Hoffmann La Roche Heterocyclic compounds useful as dual atx/ca inhibitors
WO2018167113A1 (en) 2017-03-16 2018-09-20 F. Hoffmann-La Roche Ag New bicyclic compounds as atx inhibitors
PE20200859A1 (es) * 2017-06-02 2020-08-25 Bayer Healthcare Llc Combinacion farmaceutica que comprende regonafenib y nivolumab como anticancerigeno
EP3501522A1 (en) 2017-12-22 2019-06-26 Asamedic AS Compositions comprising acetylsalicylic acid and a phosphate salt
EP3501523A1 (en) 2017-12-22 2019-06-26 Asamedic AS Two-component compositions comprising acetyl salicylic acid and a carbonate salt
KR20210156389A (ko) 2020-06-17 2021-12-27 재단법인대구경북과학기술원 레고라페닙을 유효성분으로 포함하는 염증질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1197228A4 (en) * 1999-07-02 2004-03-10 Hisamitsu Pharmaceutical Co DRUG COMPOSITIONS FOR THE TREATMENT OF COLORECTAL CANCER
US20040121004A1 (en) 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
EA010485B1 (ru) * 2003-07-23 2008-10-30 Байер Фамэсьютиклс Копэрейшн Производное n,n'-дифенилмочевины, фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с его использованием (варианты)
JP2009514921A (ja) * 2005-11-10 2009-04-09 バイエル・ヘルスケア・アクチェンゲゼルシャフト 糖尿病性神経障害を処置するためのジアリールウレア
AR062927A1 (es) 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
GB201002530D0 (en) * 2010-02-15 2010-03-31 Univ Wolverhampton The Di-aspirin derivatives
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida

Also Published As

Publication number Publication date
CL2015000744A1 (es) 2016-01-08
SI2900269T1 (sl) 2018-10-30
IL237690B (en) 2019-07-31
LT2900269T (lt) 2018-11-12
IL237690A0 (en) 2015-05-31
KR20150060869A (ko) 2015-06-03
JP6294888B2 (ja) 2018-03-14
MX2015003728A (es) 2015-09-23
DK2900269T3 (en) 2018-10-01
HRP20181462T1 (hr) 2018-11-02
EA032023B1 (ru) 2019-03-29
AU2013322854B2 (en) 2018-07-19
AU2013322854A1 (en) 2015-04-02
CA2885688A1 (en) 2014-04-03
ZA201502840B (en) 2017-11-29
HK1214169A1 (zh) 2016-07-22
US10898500B2 (en) 2021-01-26
CA2885688C (en) 2021-03-02
PT2900269T (pt) 2018-10-22
EP2900269B1 (en) 2018-08-01
EP2900269A1 (en) 2015-08-05
KR102210575B1 (ko) 2021-02-02
WO2014048881A1 (en) 2014-04-03
US20150202214A1 (en) 2015-07-23
CN104994876A (zh) 2015-10-21
SG10201702356VA (en) 2017-04-27
NZ705860A (en) 2018-07-27
ES2687985T3 (es) 2018-10-30
HUE039878T2 (hu) 2019-02-28
JP2015529234A (ja) 2015-10-05
BR112015006686B1 (pt) 2022-04-05
EA201500365A1 (ru) 2015-08-31
SG11201501963RA (en) 2015-04-29
PL2900269T3 (pl) 2019-02-28
MX357035B (es) 2018-06-25
CY1120939T1 (el) 2019-12-11
BR112015006686A2 (pt) 2019-08-27
MY183969A (en) 2021-03-17
PH12015500587A1 (en) 2015-05-11

Similar Documents

Publication Publication Date Title
RS57875B1 (sr) Kombinacija regorafeniba i acetilsalicilne kiseline za lečenje kolorektalnog kancera
JP7475402B2 (ja) 癌治療のためのレゴラフェニブとpd-1/pd-l1(2)阻害剤の併用
WO2021160708A1 (en) Combination of regorafenib and msln-ttc for treating cancer
RU2774838C2 (ru) Комбинация регорафениба и ингибиторов pd-1/pd-l1(2) для лечения рака
BR122025015903A2 (pt) Combinação de regorafenib e inibidores de pd-1/pd-l1(2), seu uso, e kit para tratamento de distúrbios hiperproliferativos